Nicox: completes capital increase, share hit

(CercleFinance.com) - Nicox announces the successful completion of its rights issue in the form of ABSAs, for total gross proceeds of E3.
3m, and thus extends its cash horizon to pursue the development of NCX 470. NB: cp -12.2%.

This operation results in the issue of 13,154,900 ABSAs (new shares each with a warrant) at a unit price of E0.25, and its new cash horizon is estimated at a minimum of end February 2025.

Ocumension Therapeutics, Nicox's long-standing partner, holds 4.82% of the capital and becomes its largest shareholder. The ophthalmology company adds that it is pursuing partnership discussions and evaluating strategic options.


Copyright (c) 2024 CercleFinance.com. All rights reserved.